Advances in mitochondrial genome editing have expanded efforts to manipulate mitochondrial DNA and model mitochondrial disease. This Review discusses the development of programmable nucleases and mitochondrial base editors, their applications in disease modelling and therapeutic correction, and the key challenges to clinical translation.